400652-50-8

Basic information

• Product Name: Carbamic acid, [(1R)-1-(aminomethyl)-2-methylpropyl]-, 1,1-dimethylethyl ester
• Synonyms: Carbamic acid, [(1R)-1-(aminomethyl)-2-methylpropyl]-, 1,1-dimethylethyl ester;N-Boc-[(R)-1-(aMinoMethyl)-2-Methylpropyl]aMine
• CAS NO: 400652-50-8
• Molecular Formula: C10H22N2O2
• Molecular Weight: 202.29388
• Product Categories: N-BOC
• Mol File: 400652-50-8.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 292.4±23.0 °C(Predicted)
• Appearance: /
• Density: 0.961±0.06 g/cm3(Predicted)
• PKA: 12.11±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [(1R)-1-(aminomethyl)-2-methylpropyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R)-1-(aminomethyl)-2-methylpropyl]-, 1,1-dimethylethyl ester(400652-50-8)
• EPA Substance Registry System: Carbamic acid, [(1R)-1-(aminomethyl)-2-methylpropyl]-, 1,1-dimethylethyl ester(400652-50-8)

Safety Data

• Hazardous Substances Data: 400652-50-8(Hazardous Substances Data)

Upstream product

• 211568-63-7 (S)-tert-butyl 1-azido-3-methylbutan-2-ylcarbamate 
• 75-52-5 nitromethane 
• 271600-32-9 [2-methyl-1-(toluene-4-sulfonyl)-propyl]-carbamic acid tert-butyl ester 
• 79069-14-0 (S)-2-<(tert-butoxycarbonyl)amino>-3-methylbutan-1-ol 
• 126301-18-6 [(2S)-2-(tert-butoxycarbonylamino)-3-methyl-butyl] methanesulfonate 
• 110694-59-2 N-tertbutyloxycarbonyl-S-valine methyl ester 
• 35150-08-4 Boc-Val-NH₂ 
• 864943-54-4 [(1S)-1-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2-methylpropyl]carbamic acid 1,1-dimethylethyl ester 
• 216319-90-3 (S)-tert-butyl 1-cyano-2-methylpropylcarbamate 
• 2026-48-4 (S)-valinol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 72-18-4 L-valine 
• 228557-24-2 benzyl N-[1-(azidomethyl)-3-methylbutyl]carbamate 
• 142554-61-8 (S)-(-)-1,1-dimethylethyl <1-(azidomethyl)-3-methylbutyl>carbamate 

Downstream Products

• 1609348-38-0 rac-tert-butyl {1-[({8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridin-3-yl}carbonyl)amino]-3-methylbutan-2-yl}carbamate 
• 1609348-37-9 rac-tert-butyl {1-[({6-chloro-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridin-3-yl}carbonyl)amino]-3-methylbutan-2-yl}carbamate 

Relevant articles and documents

Development of Chiral Organosuperbase Catalysts Consisting of Two Different Organobase Functionalities

In the field of chiral Br?nsted base catalysis, a new generation of chiral catalysts has been highly anticipated to overcome the intrinsic limitation of pronucleophiles that are applicable to the enantioselective reactions. Herein, we reveal conceptually new chiral Br?nsted base catalysts consisting of two different organobase functionalities, one of which functions as an organosuperbase and the other as the substrate recognition site. Their prominent activity, which stems from the distinctive cooperative function by the two organobases in a single catalyst molecule, was demonstrated in the unprecedented enantioselective direct Mannich-type reaction of α-phenylthioacetate as a less acidic pronucleophile. The present achievement would provide a new guiding principle for the design and development of chiral Br?nsted base catalysts and significantly broaden the utility of Br?nsted base catalysis in asymmetric organic synthesis.

TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific c

TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY

This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.